Here is our Top Docs 2025 profile on Jeffrey Zonder, M.D., who is part of the Karmanos Cancer Institute’s Multiple Myeloma and Amyloidosis Multidisciplinary Team.

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

DelveInsight's Hereditary Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current ...

Watercolour prints of local doors, painted by late Frome stalwart John Birkett-Smith, are being exhibited and sold in his ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming ...

Cardiologist Dmitry Yaranov highlights amyloidosis as an underdiagnosed cause of heart failure, often mistaken for hypertension or aging. This condition involves misfolded proteins stiffening the ...

University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in ...

(Alexandria, MN)--The 2025 Walk to End Alzheimer's disease is set for tomorrow (Saturday) in Alexandria. Registration will ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Piper Sandler representative to request meetings. A link to access the replay, ...